Pericarditis secondary to interferon alpha in chronic hepatitis C [6];Péricardite induite par l'interféron alpha au cours d'une hépatite chronique C

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 3, 2004, Pages 315-316

  Wisniewski, Benjamin ^a   Denis, Jacques ^a   Fischer, Daniel ^a   Labayle, Denis ^a  

^a CENTRE HOSPITALIER SUD FRANCILIEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ADULT; ANAMNESIS; CARDIOTOXICITY; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG RESPONSE; ECHOGRAPHY; FEMALE; HEPATITIS C; HUMAN; LABORATORY TEST; LETTER; MONOTHERAPY; PERICARDITIS; SEROLOGY; SYMPTOM; THORAX RADIOGRAPHY;

EID: 1942502190     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(04)94929-9     Document Type: Article

References (10)

1. Renault PF, Hoofnagle JH. Side effects of α interferon. Semin Liver Dis 1989;9:273-7.
2. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high dose interferon therapy for chronic hepatits C. J Hepatol 1996;25:283-91.
3. Kadayifci A, Aytemir K, Arslan M, Aksoyek S, Sivri B, Kabakci G. Interferon α does not cause significant cardiac dysfonction in patients with chronic active hepatitis. Liver 1997;17:99-102.
4. Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996;37:905-15.
5. Boonen A, Stockbrugger RW, Van Der Linden SJ. Pericarditis after therapy with interferon α for chronic hepatitis C. Clin Rheumatol 1999;18:177-9.
6. Suarez A, Vallina E, Navascues CA, Rodriguez M, Otero L, Sotorrio NG, et al. Mixed type 2 cryoglobulinemia associated with a chronic hepatitis C virus infection. Rev Clin Esp 1993;192:325-6.
7. Sonnenblick M, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991;99:557-61.
8. Lampidis TJ, Brouty-Boye D. Interferon inhibits cardiac cell function in vitro. Proc Soc Exp Biol Med 1981;166:181-5.
9. Mansat-Krzyzanowska E, Dreno B, Chiffoleau A, Litoux P. Manifestations cardio-vasculaires associées à l'interferon α 2a. Ann Med Interne 1991;142:576-81.
10. Jones GJ, Itri LM. Safety and tolerance of recombinant interferon α 2 a in cancer patients. Cancer 1986;57 (suppl):1709-15.